Skip to main content
Birkhäuser

Clinical and Biological Basis of Lung Cancer Prevention

  • Book
  • © 1998

Overview

Part of the book series: Respiratory Pharmacology and Pharmacotherapy (RPP)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (30 chapters)

Keywords

About this book

Lung cancer is a disease with pandemic public health implications as it is now the leading cause of cancer mortality throughout the world. This book results from two recent International Association for the Study of Lung Cancer (IASLC) Workshops on lung cancer prevention. It strikes a balance between considering public health approaches to tobacco control and population-based screening, advances in clinical evaluation of chemoprevention approaches, and the biology of lung carcinogenesis. Indeed, while the science of smoking cessation is evolving as new pharmacological tools are moving into clinical evaluation, the current impact of molecular diagnostics is profound. The rapidly-evolving diagnostic technologies are revolutionizing basic scientific investigation of cancer, and this trend is expected to soon spill over into the clinical practice of medicine. The evolution of economical diagnostic platforms to allow for direct bronchial epithelial evaluation in high-risk populations promises to improve the diagnostic lead-time for this disease. The hope is that enough progress will occur to permit lung cancer detection in advance of clinical cancer so that the disease can be addressed early on, while it is still confined to the site of origin. Chemoprevention, which is designed to intervene in the early phase of carcinogenesis prior to any subjective clinical manifestation of a cancer, is also generating greater research interest. Moreover, the benefit of aerosolized administration of chemoprevention agents over conventional oral administration has strong appeal and may result in the reduction of the incidence of cancer when combined with new diagnostic technologies.

Editors and Affiliations

  • Hôpital de Brabois Service de Pneumologie A, Centre Hospitalier Universitaire de Nancy, Vandoeuvre-lès-Nancy, France

    Yves Martinet

  • The Finsen Center Department of Oncology 5074, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

    Fred R. Hirsch

  • Unité de Recherche de Physipathologie Respiratoire, INSERM U14, Vandoeuvre-lès-Nancy, France

    Nadine Martinet

  • Service d’Anatomie Pathologique, Centre Hospitalier Universitaire de Nancy Hôpital Central, Nancy, France

    Jean-Michel Vignaud

  • National Cancer Institute / National Institutes of Health, Division of Clinical Sciences / Medicine Branch Cell and Cancer Biology Department, Rockville, USA

    James L. Mulshine

Bibliographic Information

  • Book Title: Clinical and Biological Basis of Lung Cancer Prevention

  • Editors: Yves Martinet, Fred R. Hirsch, Nadine Martinet, Jean-Michel Vignaud, James L. Mulshine

  • Series Title: Respiratory Pharmacology and Pharmacotherapy

  • DOI: https://doi.org/10.1007/978-3-0348-8924-7

  • Publisher: Birkhäuser Basel

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Basel AG 1998

  • Hardcover ISBN: 978-3-7643-5778-8Published: 18 December 1997

  • Softcover ISBN: 978-3-0348-9829-4Published: 05 November 2012

  • eBook ISBN: 978-3-0348-8924-7Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XVIII, 326

  • Topics: Pneumology/Respiratory System, Cancer Research

Publish with us